Ocera Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The founders of Ocera Therapeutics recognize that the medical needs of patients with gastrointestinal and liver diseases are largely unmet, and they think they can do something about it. Their goal is to develop new therapeutic products for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and liver disease sufferers by in-licensing clinical-stage compounds with promising efficacy and safety profiles.